Pharmacogenomics Study of Extreme Response to Metformin

In this collaboration with GlaxoSmithKline, University of California San Francisco and Kaiser Permanente Northern California, we propose to perform a genome-wide association study in 1,000 patients of European ancestry with extreme response phenotypes to metformin using genomewide array and human exome chip, which include rare nonsynonymous variants. Our aim is to determine whether rare variants, either acting alone or in combination, explain much of the variation in response to metformin, particularly in the extreme responder and non-responder groups.

0